ClinicalTrials.gg
TerminatedNCT03944720Updated Sep 28, 2023

Efficacy of Transvaginal Repair for Rectocele

An observational study in Rectocele and Surgery, sponsored by Consorci Sanitari de Terrassa. Terminated at 1 site in Spain. Open to female participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2023-09-28.

Sponsored by Consorci Sanitari de Terrassa · Observational

Why this study was terminated
Lack of recruitment in participating centers
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
15
Ages
18 Years to 85 Years
Sex
Female
01

Study summary

Patients with rectoceles may present a variety of symptoms such as pelvic pressure, obstructive defecation or discomfort during sexual intercourse. The main symptom of the patient probably ends up conditioning if the patient is referred to a gynaecologist or a colorectal surgeon.

Different surgical techniques have been described to repair the rectocele. The posterior colporrhaphy is the preferred approach for most gynaecologists, while the transanal repair is the most common approach for the majority of colorectal surgeons. However, the small number of prospective studies, the inconsistent inclusion criteria and the variability of the outcome measures make difficult to know what the ideal surgical approach for a rectocele repair would be. Gynaecologists usually do not assess defecatory function before a rectocele repair, and studies focused on obstructive defecation include patients with other co-existing pathologies (rectal prolapse, rectal intussusception, enterocele) that may influence the success of the repair. Moreover, functional disorders such as the paradoxical contraction of the external anal sphincter or the puborectalis muscle are not systematically reported. On the other hand, many surgeons have questioned the transvaginal approach because it has been reported that patients may present dyspareunia after the surgery, although it is not systematically evaluated.

The hypothesis of the investigators is that the transvaginal approach for rectocele repair is an effective treatment for symptoms of obstructive defecation and is not associated with sexual dysfunction when the plication of the puborectalis muscle is not performed.

02

Conditions studied

  • Rectocele
  • Surgery

Browse trials for

03

In context

Rectocele

50 studies on the registry are indexed under Rectocele; 9 are open to participants now.

This study's enrollment of 15 is below the median of 113 across 13 observational studies indexed under Rectocele.

Browse Rectocele studies →

Lead sponsor

Consorci Sanitari de Terrassa is the lead sponsor of 41 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with indication for rectocele surgical repair fulfilling the inclusion criteria

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women
  • Older than 18 year old
  • Symptoms of obstructed defecation associated to a rectocele with an indication for surgery according to the following criteria:

    1. Symptoms of obstructed defecation according to Rome III criteria: straining, sensation of incomplete evacuation, sensation of anorectal obstruction/blockage, and/or manual manoeuvres to facilitate defecation at least in 25% of defecations for the last 3 months
    2. Incomplete emptying of the rectocele on a defecography
    3. Failure of conservative treatment including dietary advice and laxatives, with persisting symptoms of obstructive defecation
    4. Recto-rectal intussusception may coexist on defecography (grade I and II of Oxford Prolapse Grading System)
    5. Non-obstructive enterocele may coexist on defecography (type A enterocele: the small bowel descends to puboccoccygeal line (PCL) during straining and returns to PCL at the end of the straining attempt without compressing the rectal ampulla or compressing it from above with no obstruction)
    6. Absence of anal sphincter dyssynergia on anorectal manometry, or successful rehabilitation after biofeedback in the case of previous dyssynergia
  • Ability to understand the surgical procedure and the questionnaires of the study
  • Written

Exclusion criteria

Exclusion Criteria:

  • Anal sphincter dyssynergia
  • Coexisting recto-anal intussusception on defecography or external rectal prolapse (grades III, IV and V Oxford Prolapse Grading System)
  • Coexisting enterocele compressing/obstructing the rectum on defecography (type B enterocele: the enterocele descends beyond the PCL to the perineum through the rectovaginal space to compress the rectal ampulla at the end of the evacuation process; type C enterocele (obstructive): the enterocele descends beyond the PCL to the perineum through the rectovaginal space to compress the rectal ampulla at the beginning of the evacuation process)
  • Slow transit constipation associated to obstructed defecation
  • Severe psychiatric disorder
  • Refusal to provide written
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
15 participants (actual)
Target follow-up
24 Months
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Change in symptoms of obstructive defecation measured by the Altomare obstructed defecation syndrome (ODS) score

    Assessment of the efficacy of the transvaginal approach for rectocele repair to improve symptoms of obstructive defecation according to the Altomare ODS score. The Altomare ODS score is a validated questionnaire to assess the severity of the obstructed defecation syndrome, consisting of eight 3- o 4-point Likert-scaled symptom items. Each of the items has four or five possible answers with scores ranging from zero (symptom free) to three or four points (more severe symptom). The ODS score is the sum of all points, with a maximum possible of 31 points.

    Time frame: Baseline, 6 months and 12 months after surgery

  2. Change in symptoms of obstructive defecation measured by the KESS score

    Assessment of the efficacy of the transvaginal approach for rectocele repair to improve symptoms of obstructive defecation according to the KESS score. The KESS (Knowles-Eccersley-Scott-Symptom) score is a validated questionnaire to assist in diagnosing constipation and in discriminating among pathophysiologic subgroups, consisting of eleven questions. Each question has four to five possible answers which are scored on an unweighted linear integer scale to produce a range between zero and three, or zero and four points. Lower scores represent symptom-free states and higher scores, increased symptom severity. The KESS score is the sum of all points, with a maximum possible of 39 points.

    Time frame: Baseline, 6 months and 12 months after surgery

Secondary outcomes

  1. Changes in sexual function

    To assess changes in the Female Sexual Function Index (FSFI) questionnaire. The FSFI score is a validated 19-item questionnaire to measure the sexual functioning in women, including six domains: desire, subjective arousal, lubrication, orgasm, satisfaction and pain. Domain scoring is as follows: desire 2-10, arousal 0-20, lubrication 0-20, orgasm 0-15, satisfaction 2-15, pain 0-15. Lower scores represent worse sexual functioning.

    Time frame: Baseline, 6 months and 12 months after surgery

  2. Assessment of morbidity related to the surgical technique

    Description of the morbidity that may be related to any surgical technique

    Time frame: Baseline, 6 months and 12 months after surgery

07

Study locations

1 site
  • Consorci Sanitari de Terrassa
    Terrassa, Barcelona 08227, Spain
08

References and documents

Individual participant data

Plan to share: No — All data will be included in the same database and analyzed together

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2019 to primary completion in Dec 2022, 41 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2019
First posted
May 9, 2019
StartActual
Jul 15, 2019
Primary completionActual
Dec 31, 2022
CompletionActual
Dec 31, 2022
Last update
Sep 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03944720
Lead sponsor
Consorci Sanitari de Terrassa
Collaborators
Hospital Universitari MútuaTerrassa, Heling HartZiekenhuis Lier, Hospital Clinico Universitario San Cecilio
Responsible party
Yolanda Ribas (Principal investigator, Consorci Sanitari de Terrassa) — Principal investigator
First posted
May 9, 2019
Start date
Jul 15, 2019
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022
Last update
Sep 28, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion